Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 301–400 of 1,001
Bischoff, S. C., & Schweinlin, A. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.04.013 · Cited by 56
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 47
Safety and tolerability review of lorcaserin in clinical trials
Greenway, F. L., Shanahan, W. R., Fain, R., Ma, T., & Rubino, D. (2016) · Clinical Obesity · doi:10.1111/cob.12159 · Cited by 39
Anesthetic Considerations in Patients Undergoing Bariatric Surgery: A Review Article
Soleimanpour, H., Safari, S., Sanaie, S., Nazari, M., & Alavian, S. M. (2017) · Anesthesiology and Pain Medicine · doi:10.5812/aapm.57568 · Cited by 40
“Although the prescribed weight loss drugs will not do magic, they may be effective, especially when combined with proper diet programs and physical activity (6).”
BackgroundZhang, P., Jia, J., Jiang, P., Zheng, W., Li, X., Song, S., & Ai, C. (2022) · Food & Function · doi:10.1039/d1fo04012j · Cited by 37
Medical devices for the treatment of obesity
Lee, P. C., & Dixon, J. B. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.80 · Cited by 39
Caixàs, A., Villaró, M., Irigoyen, C. A., Montalvá, J.-C., Lecube, A., Fernández-García, J.-M., Corio, R., Bellido, D., Llisterri, J. L., & Tinahones, F. J. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2019.10.014 · Cited by 54
A Critical Review on Obesity: Herbal Approach, Bioactive Compounds, and Their Mechanism
Kumar, M., Kaushik, D., Kaur, J., Proestos, C., Öz, F., Öz, E., Gupta, P., Kundu, P., Kaur, A., Anisha, A., et al. (2022) · Applied Sciences · doi:10.3390/app12168342 · Cited by 46
Rankin, W. A., & Wittert, G. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000232 · Cited by 36
Staffileno, B. A., Tangney, C., & Fogg, L. (2017) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000409 · Cited by 39
“Although these women were relatively young and prehypertensive, they were overweight or obese according current national guidelines.(48,49) The Consort diagram illustrates the flow of participants (Figure 1).”
BackgroundTreatment of Obesity in Primary Care
Tsai, A. G., Remmert, J. E., Butryn, M. L., & Wadden, T. A. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.005 · Cited by 38
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 38
New Insight on In Vitro Biological Activities of Sulfated Polysaccharides from Ulvophyte Green Algae
Nurkolis, F., Kurniawan, R., Kurniatanty, I., Park, M. N., Moon, M., Fatimah, S., Gunawan, W. B., Surya, R., Taslim, N. A., Song, H., et al. (2023) · Molecules · doi:10.3390/molecules28114531 · Cited by 40
“Obesity is characterized by an abnormal lipid accumulation attributed to lipase activity [27], but the physiological consequences of obesity are much more concerning and can require treatment that is still expensive [28,29].”
BackgroundMilano, W., Biasio, V. D., Munzio, W. D., Foggia, G., & Capasso, A. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200515112853 · Cited by 36
Treating the Chronic Disease of Obesity
Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.005 · Cited by 33
Guo, H., Yang, J., Huang, J., Xu, L., Lv, Y., Wang, Y., Ren, J., Feng, Y., Zheng, Q., & Li, L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100162 · Cited by 32
“For those unable to control their weight through lifestyle changes or additional comorbidities, pharmacological treatment is often essential [9,10].”
Yadav, M., Kumar, T., Kanakan, A., Maurya, R., Pandey, R., & Chauhan, N. S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932795 · Cited by 38
“To treat obesity, the gastrointestinal absorption of fats should be first reduced (Apovian et al., 2015).”
BackgroundRubino, D., Pedersen, S. D., Connery, L. E., Cao, D., Chigutsa, F. B., Stefański, A., Brumm, J. F., Griffin, R. M., & Gerber, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16176 · Cited by 50
Guidelines for Obesity Management
Ryan, D. H. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.003 · Cited by 32
Self-citationObesity: Overview of Weight Management
Mehta, M., Istfan, N. W., & Apovian, C. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.001 · Cited by 42
Self-citationRyan, D. H., Barquera, S., Cavalcanti, O. B., & Ralston, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-45009-0_39 · Cited by 64
Self-citationBrown, J. A., Sagante, A., Mayer, T. A., Wright, A., Bugescu, R., Fuller, P. M., & Leinninger, G. M. (2018) · Endocrinology · doi:10.1210/en.2018-00311 · Cited by 38
Pantalone, K. M., Smolarz, B. G., Ramasamy, A., Baz Hecht, M., Harty, B. J., Rogen, B., Griebeler, M. L., Borukh, E., Young, J. B., & Burguera, B. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.16595 · Cited by 31
Su, N., Li, Y., Xu, T., Li, L., Kwong, J. S.-W., Du, H., Ren, K., Li, Q., Li, J., Sun, X., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.028 · Cited by 36
Anti-obesity efficacy of the selected high altitude Himalayan herbs: in vitro studies
Kumar, M., Guleria, S., Chawla, P., Khan, A. U., Modi, V. K., Kumar, N., & Kaushik, R. (2020) · Journal of Food Science and Technology · doi:10.1007/s13197-020-04341-5 · Cited by 31
ABDELFATTAH, D. S. E., Fouad, M. A., ElMeshad, A. N., El-Nabarawi, M. A., & Elhabal, S. F. (2024) · Nutrients · doi:10.3390/nu16020310 · Cited by 36
“Treatment options for obesity vary widely and include calorie restriction paired with increased physical activity, weight loss surgery, prescription weight-loss medicines, and lifestyle adjustment [12].”
BackgroundImpact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.090 · Cited by 34
“Endocrine Society Clinical Practice Guidelines on the Pharmacological Management of Obesity recommends that basal insulin should be prioritized over other insulin therapy, when indicated, and that combination therapy with weight loss-associated glucose-lowering medications should be considered to help counteract some…”
BackgroundPagano, E. S., Spinedi, E., & Gagliardino, J. J. (2016) · Neuroendocrinology · doi:10.1159/000453317 · Cited by 35
Hankosky, E. R., Chinthammit, C., Meeks, A., Huang, A., Ward, J. M., Mojdami, D., & Hunter, T. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16290 · Cited by 39
Inflammatory responses to dietary and surgical weight loss in male and female mice
Griffin, C. A., Hutch, C. R., Abrishami, S., Stelmak, D., Eter, L., Li, Z., Chang, E. T., Agarwal, D., Zamarron, B. F., Varghese, M., et al. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0229-7 · Cited by 31
Hales, C. M., Gu, Q., Ogden, C. L., & Yanovski, S. Z. (2021) · Obesity · doi:10.1002/oby.23299 · Cited by 30
Cardiovascular Disease Risk Reduction and Body Mass Index
Samson, R., Ennezat, P. V., Jemtel, T. H. L., & Oparil, S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01213-5 · Cited by 34
Staffileno, B. A., Zschunke, J., Weber, M., Gross, L., Fogg, L., & Tangney, C. (2016) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000360 · Cited by 35
Anti-Obesity Effects of the Flower of Prunus persica in High-Fat Diet-Induced Obese Mice
Song, J., Kim, Y.-S., Kim, L., Park, H., Lee, D., & Kim, H. (2019) · Nutrients · doi:10.3390/nu11092176 · Cited by 36
“Medications approved for overweight and obesity treatment include orlistat, lorcaserin, and liraglutide, and these drugs are intended only for patients with a body mass index (BMI) ≥ 30 or BMI ≥ 27 with comorbidities [3].”
BackgroundTronieri, J. S., Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Alamuddin, N., Gruber, K., Leonard, S., & Chao, A. M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.03.005 · Cited by 29
“Weight loss with pharmacotherapy, as with lifestyle modification, typically plateaus after approximately 6 to 9 months of treatment (1,4,5).”
BackgroundHaber, R., Zarzour, F., Ghezzawi, M., Saadeh, N., Bacha, D. S., Jebbawi, L. A., Chakhtoura, M., & Mantzoros, C. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15501 · Cited by 39
Facing Morbid Obesity: How to Approach It
Ricci, M. A., VUONO, S. D., Scavizzi, M., Gentili, A., & Lupattelli, G. (2015) · Angiology · doi:10.1177/0003319715595735 · Cited by 40
“Lorcaserin, a serotoninergic drug with anorectic properties, and phentermine/topiramate, a combination of a noradrenergic drug and an anticonvulsant with weight loss side effects, till now have been approved only by Food and Drug Administration (FDA) and not by European Medicine Agency (EMA), while naltrexone/bupropio…”
BackgroundInfluentialSudlow, A. C., le Roux, C. W., & Pournaras, D. J. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04206-7 · Cited by 34
Person-centred Obesity Care – Techniques, Thresholds, Tools and Targets
Kalra, S., Kapoor, N., Kota, S. K., & Das, S. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.1.11 · Cited by 32
Physicians certified by the American Board of Obesity Medicine provide evidence‐based care
Gudzune, K. A., Wickham, E. P., Schmidt, S. L., & Stanford, F. C. (2020) · Clinical Obesity · doi:10.1111/cob.12407 · Cited by 29
Oliveira, V., Kwitek, A. E., Sigmund, C. D., Morselli, L. L., & Grobe, J. L. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.14513 · Cited by 31
Oxytocin as an Anti-obesity Treatment
Niu, J., Tong, J., & Blevins, J. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.743546 · Cited by 34
Ruiz‐Malagón, A. J., Rodríguez‐Sojo, M. J., Hidalgo‐Garcia, L., Molina‐Tijeras, J. A., García, F., Pischel, I., Romero, M., Duarte, J., Diez‐Echave, P., Rodríguez‐Cabezas, M. E., et al. (2022) · Antioxidants · doi:10.3390/antiox11061073 · Cited by 35
“Unfortunately, most of them have adverse effects that can limit their use [19].”
BackgroundMedical and Surgical Treatment of Obesity
Reid, T. J., & Körner, J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.03.002 · Cited by 40
Pahwa, R., ADAMS-HUET, B. A., & Jialal, I. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.010 · Cited by 29
Pharmacotherapy for weight management in the VHA
Semla, T. P., Ruser, C., Good, C. B., Yanovski, S. Z., Ames, D., Copeland, L. A., Billington, C., Ferguson, U. I., Aronne, L. J., Wadden, T. A., et al. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3949-y · Cited by 28
Self-citationLi, H., Yu, G., Huang, Q., Yang, B., Nie, J., Liu, Y., & Tu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116150 · Cited by 38
Wekker, V., Karsten, M. D. A., Painter, R. C., van de Beek, C., Groen, H., Mol, B. W., Hoek, A., Laan, E. T. M., & Roseboom, T. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205934 · Cited by 40
Obesity medications: A narrative review of current and emerging agents
Qi, Q., Cox, A., McNeil, S. E., & Sumithran, P. (2024) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2024.100472 · Cited by 42
Pharmacological management of polycystic ovary syndrome
Ee, C., & Tay, C. T. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.030 · Cited by 34
“13 Concurrent effective contraception is required if pregnancy is possible because there is insufficient safety data on the use of GLP-1 receptor agonists in pregnancy.”
BackgroundCorrado, A., Guadagni, I., Picarelli, G., & Variola, A. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70080 · Cited by 32
Current Long-Term Pharmacotherapies for the Management of Obesity
Kim, B.-Y., Kang, S. M., Kang, J., Kim, K. K., Kim, B., Kim, S. J., Kim, Y., Kim, J. H., Kim, J. H., Nam, G. E., et al. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20010 · Cited by 29
Wekker, V., Huvinen, E., van Dammen, L., Rönö, K., Painter, R. C., Zwinderman, A. H., van de Beek, C., Sarkola, T., Mol, B. W., Groen, H., et al. (2018) · European Journal of Public Health · doi:10.1093/eurpub/cky222 · Cited by 31
Gharaibeh, N. E., Rahhal, M.-N., Rahimi, L., & Ismail‐Beigi, F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s212715 · Cited by 31
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“The most important side effects of these drugs are related to their gastrointestinal actions of decreasing gastric emptying time and include nausea and constipation; however, diarrhea has been shown to occur as well.(133) Weight loss may in part be due to these gastrointestinal side effects.”
BackgroundInfluentialFitch, A., Malhotra, S., & Conroy, R. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100110 · Cited by 33
Obesity at Menopause: An Expanding Problem
Atapattu, P. M. (2015) · Journal of Patient Care · doi:10.4172/2573-4598.1000103 · Cited by 30
“Orlistat, Phentermine, Topiramate, Lorcaserin, Natrexone/bupropion, Diethylpropion, Phendimetrazine and Benzphetamine are available for managing obesity [117,120,121].”
BackgroundObesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?
Eleazu, C. O., Omar, N., Lim, O. Z., Yeoh, B. S., Hussain, N. H. N., & Mohamed, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00787 · Cited by 30
Natural products in the management of obesity: Fundamental mechanisms and pharmacotherapy
Chan, Y., Ng, S. W., Tan, J. Z. X., Gupta, G., Negi, P., Thangavelu, L. P., Balusamy, S. R., Perumalsamy, H., Yap, W. H., Singh, S. K., et al. (2021) · South African Journal of Botany · doi:10.1016/j.sajb.2021.07.026 · Cited by 35
Yoo, H.-J., Yoon, H.-Y., Yee, J., & Gwak, H. S. (2021) · Pharmaceuticals · doi:10.3390/ph14111198 · Cited by 34
“used to manage obesity, especially when body mass index (BMI) exceeds 30 kg/m2 or in the context of comorbid diseases and a BMI exceeding 27 kg/m2 [8].”
MethodHuang, T., Howse, F. M., Stachenfeld, N. S., & Usselman, C. W. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00399.2022 · Cited by 34
Five-year Weight Loss Maintenance With Obesity Pharmacotherapy
Weintraub, M. A., D’Angelo, D., Tchang, B. G., Sahagun, A., Andre, C., Aronne, L. J., & Shukla, A. P. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad100 · Cited by 33
Self-citationNeuropeptides Modulate Feeding via the Dopamine Reward Pathway
Jin, R., Sun, S., Hu, Y., Zhang, H., & Sun, X. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03954-4 · Cited by 28
Harper, C., Pattinson, A. L., Fernando, H. A., Zibellini, J., Seimon, R. V., & Sainsbury, A. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0025 · Cited by 27
“International [74, 75] and national [76] organizations recommend that pharmacotherapy be considered for the treatment of obesity, as an adjunct to lifestyle changes, for people with a BMI > 30 kg/m2, or BMI ≥ 27 kg/m2 with at least one comorbid medical condition such as hypertension, dyslipidemia, type 2 diabetes mell…”
BackgroundSilveira, É. A., Vieira, L. L., Jardim, T. V., & de Souza, J. D. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160182 · Cited by 72
Devices and Endoscopic Bariatric Therapies for Obesity
Saunders, K. H., Igel, L. I., Saumoy, M., Sharaiha, R. Z., & Aronne, L. J. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0307-x · Cited by 26
Self-citationEl-Sayed, S., & Ibrahim, H. M. (2020) · Folia Morphologica · doi:10.5603/fm.a2019.0100 · Cited by 27
“Nowadays, obesity is a major dilemma for all the health workers over the globe and becomes a leading cause of many diseases as cardiovascular diseases, diabetes, and cancer [31] with significant multiple endocrine systems affection [5], including thyroid dysfunction [8].”
BackgroundCardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
“Recent reviews of weight loss outcomes from these the anti-obesity medications have been published (4, 5).”
BackgroundThomas, D. D., Waring, M. E., Ameli, O., Reisman, J. I., & Vimalananda, V. G. (2019) · Obesity · doi:10.1002/oby.22503 · Cited by 25
“Weight-management medications (WMM), when added to lifestyle interventions, increase the likelihood of achieving ≥ 5% weight loss (8).”
BackgroundMethodInvestigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Griebeler, M. L., Butsch, W. S., Rodriguez, P., Lomeli, L., Kampert, M., Makin, V., Alwahab, U. A., Borukh, E., Daigle, E., Bena, J., et al. (2022) · Obesity · doi:10.1002/oby.23548 · Cited by 25
GIUSTI, E. M., SPATOLA, C. A., BRUNANI, A., KUMBHARE, D., ORAL, A., ILIEVA, E., KIEKENS, C., PIETRABISSA, G., MANZONI, G. M., IMAMURA, M., et al. (2020) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.20.06232-2 · Cited by 25
A bibliometric analysis of obesity in marketing research
Onjewu, A.-K. E., Sadraei, R., & Jafari‐Sadeghi, V. (2022) · EuroMed Journal of Business · doi:10.1108/emjb-03-2022-0051 · Cited by 29
Pokushalov, E., Ponomarenko, A., Garcia, C., Алексеевна, П. И., Shrainer, E., Seryakova, M., Johnson, M., & Miller, R. D. (2024) · Nutrients · doi:10.3390/nu16040557 · Cited by 30
“Pharmacotherapy has emerged as an adjunct or alternative when lifestyle modifications are insufficient [10], but it is not devoid of safety concerns and side effects [11].”
BackgroundEisa, N., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70666 · Cited by 50
Shaw Tronieri, J., Wadden, T. A., Berkowitz, R. I., Chao, A. M., Pearl, R. L., Alamuddin, N., Leonard, S. M., Carvajal, R., Bakizada, Z. M., Pinkasavage, E., et al. (2018) · Obesity · doi:10.1002/oby.22081 · Cited by 25
“Drug Administration (FDA) for chronic weight management offer another option (7).”
BackgroundIgel, L. I., Saunders, K. H., & Fins, J. J. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0740-z · Cited by 25
Leveraging Genomic Associations in Precision Digital Care for Weight Loss: Cohort Study
Sinha, R., Kachru, D., Ricchetti, R. R., Singh-Rambiritch, S., Muthukumar, K., Singaravel, V., Irudayanathan, C., Reddy-Sinha, C., Junaid, I., Sharma, G., et al. (2021) · Journal of Medical Internet Research · doi:10.2196/25401 · Cited by 30
“Obesity-associated biological factors include, but are far from limited to, genetics and epigenetics, microbiome composition, age, circadian rhythm disruption, pharmaceutical interactions, and comorbidities and their management [6,7].”
An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
Enright, C., Thomas, E., & Saxon, D. R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac195 · Cited by 32
“In addition to lifestyle counseling, a central point of caring for patients with overweight or obesity involves reviewing their use of medications that promote weight gain and prescribing drugs that are weight neutral or that promote weight loss [24,26].”
InfluentialReview of 3‐year outcomes of a very‐low‐energy diet‐based outpatient obesity treatment programme
Sumithran, P., Prendergast, L. A., Haywood, C. J., Houlihan, C. A., & Proietto, J. (2016) · Clinical Obesity · doi:10.1111/cob.12135 · Cited by 27
Comprehensive care for patients with obesity: An Obesity Medicine Association Position Statement
Fitch, A., Alexander, L., Brown, C. F., & Bays, H. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100070 · Cited by 24
Vosburg, R. W., El Chaar, M., El Djouzi, S., Docimo, S., Choi, D., LaMasters, T., Srivastava, G., Shukla, A. P., Oviedo, R. J., Fitch, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.07.002 · Cited by 24
Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24
“0 mg/d) is approved for weight loss treatment in patients with obesity among all hypoglycaemic drugs [26].”
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Ali, M. M., Parveen, S., Williams, V. R., Dons, R. F., & Uwaifo, G. I. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100341 · Cited by 42
“The current recommendation is to start medication to assist with weight loss in people with a BMI greater than 30 kg/m 2 , or a BMI greater than 27 kg/m 2 with associated comorbidities related to obesity [197,198].”
BackgroundEvolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 30
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Song, H. J., Hwang, J., Pi, S., Ahn, S., Heo, Y., Park, S., & Kwon, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197057 · Cited by 27
Murugan, D. D., Balan, D., & Wong, P. (2021) · Phytotherapy Research · doi:10.1002/ptr.7205 · Cited by 28
“These together with phar- macological intervention may provide additional benefits in ameliorat- ing comorbidities and promoting adherence to behavior modifications, which in turn may improve physical functions for greater physical activity (Apovian et al., 2015).”
BackgroundThe risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
A Guideline-Directed Approach to Obesity Treatment
Chao, A. M., Paul, A. M., Hodgkins, J., & Wadden, T. A. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0001 · Cited by 35
Singh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 37
“According to 2015 Endocrine Society Guidelines, diet, exercise, and behavioral therapy should be a part of all obesity management approaches; [87] however, for the majority of individuals living with obesity, lifestyle modification alone is inadequate.”
Tronieri, J. S., Fabricatore, A. N., Wadden, T. A., Auerbach, P., Endahl, L. A., Sugimoto, D. H., & Rubino, D. (2020) · Obesity Facts · doi:10.1159/000511130 · Cited by 44
Medical treatment of weight loss in children and adolescents with obesity
Calcaterra, V., Rossi, V., Mari, A., Casini, F., Bergamaschi, F., Zuccotti, G., & Fabiano, V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106471 · Cited by 27
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs
Otsuka, K., Nishiyama, H., Kuriki, D., Kawada, N., & Ochiya, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.001 · Cited by 30
Apovian, C. M., & Aronne, L. J. (2015) · Circulation · doi:10.1161/circulationaha.114.010772 · Cited by 31
Self-citationMaric, T., Kanu, C., Johnson, M. R., & Savvidou, M. D. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.005 · Cited by 24
Recognizing obesity as a disease
Christensen, S. M. (2020) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000482 · Cited by 26
Obesity in kidney transplantation
Cocco, P. D., Okoye, O. T., Almario, J., Benedetti, E., Tzvetanov, I. G., & Spaggiari, M. (2019) · Transplant International · doi:10.1111/tri.13547 · Cited by 25
Anti-obesity drug therapy in clinical practice: Evidence of a poor prescriptive attitude
Squadrito, F., Rottura, M., Irrera, N., Minutoli, L., Bitto, A., Barbieri, M. A., Cicala, G., Mecchio, A., Pallio, G., Marino, S., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110320 · Cited by 22
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.